1/8/2010

Pfizer tapped DebioPharm Group to conduct a late-stage trial of tremelimumab in patients with unresectable, Stage IV melanoma. Pfizer, which abandoned its own Phase III trial after advice from an independent board, will still be responsible for global marketing of the drug.

Full Story:
CNNMoney

Related Summaries